MarketCapExport financials
OraSure Technologies (OSUR)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
OraSure Technologies Income Statement 2025-2008 | OSUR
Brief overview of financial results at OraSure Technologies
The comparison covers a five-year financial horizon. Revenue reported by OraSure Technologies was 172 million dollars at the beginning of the period and 115 million dollars at the end. The cumulative result was −33%, corresponding to roughly −7.7% per year. The negative rate indicates weakening core operations.
At the gross-profit level, the result moved from $102 million to $48.2 million, a change of −52.7%. Direct costs outpaced revenue, limiting the benefit of changes in sales. The gross margin was 59.3% at the start and 41.9% at the end. Weakening gross profitability reduces the quality of the top-line trend.
EBITDA changed from $4.2 million to −$61.8 million (−1567.4%). EBITDA underperformed the top-line trend. The EBITDA share of revenue changed from 2.5% to −53.7%. Operating return per unit of revenue declined.
Across the five years, the net result shifted from −$14.9 million to −$68.7 million. The negative result deepened, showing weaker final efficiency.
Market value was $1 billion at the start and $235 million at the end. Market value lagged the financial performance.
Financial takeaway
The indicators point to a weaker financial profile. Caution is warranted because of pressure from direct costs, weaker operating efficiency and lower investor confidence. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.
Annual Income Statement OraSure Technologies
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
235 M | 259 M | 507 M | 464 M | 637 M | 1.03 B | 451 M | 771 M | 1.29 B | 482 M | 308 M | 514 M | 334 M | 361 M | 520 M | 201 M | - | - |
Shares |
73.5 M | 74.4 M | 73.3 M | 72.5 M | 72 M | 67.5 M | 61.7 M | 61.1 M | 59 M | 55.6 M | 56.4 M | 55.9 M | 55.6 M | 51.5 M | 46.9 M | 46.2 M | - | - |
Historical Prices |
3.2 | 3.48 | 6.91 | 6.4 | 8.85 | 15.2 | 7.05 | 12.8 | 21.8 | 8.82 | 5.47 | 9.19 | 5.87 | 7.05 | 11.1 | 4.36 | 3.78 | 5.39 |
Net Income |
-68.7 M | -19.5 M | 53.7 M | -17.1 M | -23 M | -14.9 M | 16.7 M | 20.4 M | 30.9 M | 19.7 M | 8.17 M | -4.61 M | -11.2 M | -15.1 M | -8.84 M | -3.5 M | -7.81 M | - |
Revenue |
115 M | 186 M | 405 M | 387 M | 234 M | 172 M | 155 M | 182 M | 167 M | 128 M | 120 M | 106 M | 98.9 M | 87.8 M | 81.9 M | 75 M | 77 M | - |
Cost of Revenue |
66.8 M | 106 M | 234 M | 239 M | 116 M | 69.9 M | 60 M | 68.1 M | 68.1 M | 40.2 M | - | - | - | - | - | - | - | - |
Gross Profit |
48.2 M | 79.4 M | 172 M | 148 M | 118 M | 102 M | 94.6 M | 114 M | 99 M | 88 M | 80.3 M | 66.6 M | 58.6 M | 55.6 M | 51.7 M | 47.4 M | 47.1 M | - |
Operating Income |
-72 M | -28.2 M | 32.7 M | -22.2 M | -10.2 M | -5.18 M | 18.6 M | 28.4 M | 40.2 M | 20.3 M | 8.06 M | -4.8 M | -12.2 M | -16.3 M | -9.4 M | -3.35 M | -8.79 M | - |
Interest Expense |
229 K | -380 K | 17.8 M | 3.45 M | 872 K | 1.65 M | 2.72 M | 3.29 M | 794 K | 58 K | 774 K | 531 K | 200 K | 172 K | 316 K | 316 K | 361 K | - |
EBITDA |
-61.8 M | -17.4 M | 53.6 M | -6.85 M | 1.49 M | 4.21 M | 15.5 M | 35.7 M | 34.1 M | 26 M | 13.8 M | -4 M | -13.9 M | -9.02 M | -4.51 M | -342 K | -5.74 M | - |
Operating Expenses |
120 M | 108 M | 139 M | 171 M | 128 M | 107 M | 86.8 M | 85.2 M | 71.2 M | 67.8 M | 72.2 M | 76.9 M | 79.1 M | 71.8 M | 61.1 M | 50.7 M | 55.9 M | - |
General and Administrative Expenses |
47.7 M | 46.2 M | 58.2 M | 68.2 M | 50.3 M | 42.7 M | 35.3 M | 38.3 M | 29.3 M | 28.4 M | 25.5 M | 23.8 M | 21.7 M | 22.3 M | 20.3 M | 16.8 M | 16.8 M | - |
All numbers in USD currency
Quarterly Income Statement OraSure Technologies
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
69 M | 69.7 M | 73 M | 74.5 M | 74.9 M | 74.6 M | 74.6 M | 74.2 M | 73.9 M | 73.5 M | 73.5 M | 73.3 M | 73.1 M | 72.7 M | 72.6 M | 72.5 M | 72.2 M | 72.1 M | 72 M | 72 M | 71.9 M | 71.7 M | 71.5 M | 64.7 M | 61.9 M | 61.7 M | 61.7 M | 61.7 M | 61.5 M | 61.3 M | 61.2 M | 61.1 M | 60.9 M | 60.7 M | 60.1 M | 58.5 M | 56.9 M | 56 M | 55.7 M | 55.5 M | 55.5 M | 55.7 M | 56.5 M | 56.5 M | 56.3 M | 56.2 M | 56 M | 55.9 M | 55.8 M | 55.6 M | 55.6 M | 55.6 M | 55.4 M | 55.3 M | 54.4 M | 48.2 M | 47.8 K | 47.4 M | 47 M | 46.8 M | 46.5 M |
Net Income |
6.25 M | -22.4 M | -13.7 M | -19.7 M | -16 M | - | -4.51 M | -615 K | -3.58 M | - | 11.2 M | -4.8 M | 27.2 M | - | 5.27 M | -18.6 M | -19.9 M | - | -15 M | -1.36 M | 3.77 M | - | 1.04 M | -10.5 M | -7.33 M | 2.44 M | 13.1 M | 4.4 M | -3.26 M | 10.3 M | 8.1 M | 4.12 M | -2.12 M | 7.32 M | 5.76 M | 5.43 M | 12.4 M | 7.2 M | 6.24 M | 3.84 M | 2.45 M | 4.62 M | 1.47 M | 1.97 M | 113 K | -2.65 M | 1.14 M | 2.53 M | -5.63 M | 6.21 M | -1.89 M | -5.28 M | -10.2 M | -5.87 M | -2.44 M | -3.56 M | -3.25 M | 115 K | -3.92 M | -2.44 M | -2.6 M |
Revenue |
30.6 M | 27.9 M | 27.1 M | 31.2 M | 29.9 M | - | 39.9 M | 54.3 M | 54.1 M | - | 89.2 M | 85.4 M | 155 M | - | 116 M | 80.2 M | 67.7 M | - | 53.9 M | 57.6 M | 58.6 M | - | 48 M | 29.3 M | 31.6 M | 49.7 M | 36 M | 38.8 M | 30.1 M | 50.2 M | 45.9 M | 43.6 M | 42 M | 52 M | 42.3 M | 40.2 M | 32.5 M | 35.5 M | 32.3 M | 31.4 M | 29.1 M | 32.4 M | 29.9 M | 30.4 M | 27.1 M | 28.7 M | 27.8 M | 26.4 M | 23.5 M | 28.8 M | 24.7 M | 24.3 M | 21.2 M | 22.1 M | 22.1 M | 22.6 M | 20.9 M | 23.7 M | 21.7 M | 19.1 M | 17.4 M |
Cost of Revenue |
17.3 M | 16.1 M | 15.3 M | 18.1 M | 17.6 M | - | 22.8 M | 29.6 M | 30.1 M | - | 44.8 M | 59.1 M | 89.1 M | - | 70.3 M | 52.4 M | 43.4 M | - | 32.4 M | 26.9 M | 20.3 M | - | 17.7 M | 12 M | 15.5 M | - | 14.3 M | 13.8 M | 12 M | - | 17.3 M | 17.7 M | 17.5 M | - | 17.7 M | 14.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
13.3 M | 11.8 M | 11.8 M | 13.2 M | 12.3 M | - | 17.1 M | 24.7 M | 24.1 M | - | 44.3 M | 26.4 M | 65.8 M | - | 46.2 M | 27.8 M | 24.3 M | - | 21.5 M | 30.7 M | 38.3 M | - | 30.3 M | 17.3 M | 16.1 M | - | 21.6 M | 25 M | 18.1 M | - | 28.5 M | 25.9 M | 24.5 M | - | 24.6 M | 25.5 M | 20.3 M | - | 22.7 M | 21.1 M | 20.3 M | - | 20.7 M | 20.7 M | 17 M | - | 18.7 M | 16 M | 13.9 M | - | 14.9 M | 14.5 M | 12 M | - | 13.9 M | 14.7 M | 13.7 M | - | 13.6 M | 12.3 M | 11.3 M |
Operating Income |
5.44 M | -23.3 M | -16.1 M | -18 M | -17.8 M | - | -6 M | -2.74 M | -7.09 M | - | 10.9 M | -6.43 M | 24.3 M | - | 875 K | -21.5 M | -16.2 M | - | -13 M | 1.8 M | 10.4 M | - | 4.38 M | -9.4 M | -8.05 M | 4.08 M | 13.1 M | 5.28 M | -3.81 M | 12.5 M | 10.9 M | 5.56 M | -498 K | 10.2 M | 7.32 M | 6.89 M | 15.9 M | 7.07 M | 6.14 M | 4.35 M | 2.7 M | 4.09 M | 1.54 M | 2.72 M | -291 K | -2.56 M | 882 K | 2.5 M | -5.62 M | 6.06 M | -2.06 M | -5.58 M | -10.6 M | -6.15 M | -2.93 M | -3.54 M | -3.65 M | -281 K | -4.2 M | -2.36 M | -2.55 M |
Interest Expense |
235 K | 169 K | 154 K | - | -21 K | - | 95 K | -43 K | 271 K | - | 2.61 M | 1.47 M | 2.67 M | - | 3.26 M | 1.71 M | 168 K | - | 100 K | 448 K | -119 K | - | 314 K | 216 K | 1.43 M | 477 K | 1.2 M | 524 K | 524 K | 1.63 M | 510 K | 736 K | 412 K | 118 K | 113 K | 96 K | 467 K | 92 K | 498 K | -340 K | -192 K | 379 K | 81 K | -95 K | 409 K | 287 K | 268 K | -142 K | 118 K | 164 K | 41 K | 42 K | -47 K | 26 K | 22 K | 74 K | 75 K | -158 K | 85.1 K | 79.6 K | 78.2 K |
EBITDA |
7.81 M | -20.9 M | -13.6 M | -15.5 M | -14.9 M | - | -2.95 M | -134 K | -4.37 M | - | - | - | 28 M | - | 12.3 M | -14 M | -12.5 M | - | -4.53 M | 6.94 M | 12.9 M | - | 11.3 M | -4.91 M | -5.88 M | 4.08 M | 18.6 M | 8.9 M | -2.08 M | 12.5 M | 12.7 M | 7.44 M | 1.37 M | 10.2 M | 9.02 M | 8.36 M | 17.3 M | 7.07 M | 7.56 M | 5.74 M | 4.05 M | 4.09 M | 2.95 M | 4.16 M | 1.12 M | -2.56 M | 2.51 M | 4.07 M | -4.08 M | 6.06 M | -435 K | -3.96 M | -8.99 M | -6.15 M | -1.09 M | -1.74 M | -1.84 M | -281 K | -2.88 M | -675 K | -1.72 M |
Operating Expenses |
7.88 M | 35.1 M | 27.9 M | 31.2 M | 30 M | - | 23.1 M | 27.4 M | 31.2 M | - | 33.4 M | 32.8 M | 41.5 M | - | 45.3 M | 49.3 M | 40.5 M | - | 34.5 M | 28.9 M | 27.9 M | - | 25.9 M | 26.7 M | 24.2 M | - | 8.59 M | 19.7 M | 21.9 M | - | 17.7 M | 20.3 M | 25 M | - | 17.3 M | 18.6 M | 4.44 M | - | 16.5 M | 16.7 M | 17.6 M | - | 19.1 M | 18 M | 17.3 M | - | 17.8 M | 13.5 M | 19.5 M | - | 17 M | 20.1 M | 22.6 M | - | 16.8 M | 18.2 M | 17.4 M | - | 17.8 M | 14.6 M | 13.8 M |
General and Administrative Expenses |
14.4 M | 14.6 M | 11.1 M | 12.7 M | 14.1 M | - | 9.83 M | 11.8 M | 11.6 M | - | 10.1 M | 16.4 M | 17.7 M | - | 15.5 M | 17.6 M | 19.2 M | - | 12.5 M | 11 M | 10.2 M | - | 10.1 M | 10.3 M | 10.1 M | - | 7.56 M | 7.26 M | 8.93 M | - | 6.53 M | 8.65 M | 13.4 M | - | 6.94 M | 7.75 M | 7.09 M | - | 6.91 M | 6.35 M | 6.54 M | - | 6.93 M | 6.08 M | 5.96 M | - | 5.62 M | 5.98 M | 5.72 M | - | 5.34 M | 5.01 M | 5.39 M | - | 5.22 M | 6.11 M | 6.07 M | - | 6.51 M | 4.13 M | 4.47 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company OraSure Technologies (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M |  USA |
 |
electroCore
ECOR
|
$ 11.42 | 2.46 % | $ 96.9 K | USA |
 |
Alcon
ALC
|
$ 65.39 | 0.02 % | $ 32.3 B |  Schweiz |
 |
Glaukos Corporation
GKOS
|
$ 153.49 | 0.19 % | $ 8.78 B | USA |
 |
Haemonetics Corporation
HAE
|
$ 106.82 | 0.01 % | $ 5.04 B | USA |
 |
Harvard Bioscience
HBIO
|
$ 8.05 | 1.64 % | $ 357 M | USA |
 |
InfuSystem Holdings
INFU
|
$ 12.7 | 2.26 % | $ 262 M | USA |
 |
iRhythm Technologies
IRTC
|
$ 111.75 | 1.1 % | $ 3.58 B | USA |
 |
Intuitive Surgical
ISRG
|
$ 398.3 | 0.06 % | $ 142 B | USA |
 |
AngioDynamics
ANGO
|
$ 15.51 | 0.26 % | $ 644 M | USA |
 |
Repro Med Systems
KRMD
|
$ 3.27 | 2.42 % | $ 151 M | USA |
 |
LeMaitre Vascular
LMAT
|
$ 80.58 | 0.12 % | $ 1.82 B | USA |
 |
Microbot Medical
MBOT
|
$ 1.31 | 0.36 % | $ 60 M |  Israel |
 |
Merit Medical Systems
MMSI
|
$ 87.07 | 0.1 % | $ 5.15 B | USA |
 |
Nephros
NEPH
|
$ 4.29 | 2.88 % | $ 45.5 M | USA |
 |
Envista Holdings Corporation
NVST
|
$ 23.82 | 0.41 % | $ 4 B | USA |
 |
Pro-Dex
PDEX
|
$ 71.94 | 0.12 % | $ 232 B | USA |
 |
Pulse Biosciences
PLSE
|
$ 51.98 | 0.25 % | $ 3.5 B | USA |
 |
Repligen Corporation
RGEN
|
$ 184.53 | 0.81 % | $ 10.4 M | USA |
 |
Retractable Technologies
RVP
|
$ 0.7 | 0.36 % | $ 21 M | USA |
 |
AtriCure
ATRC
|
$ 59.96 | 1.91 % | $ 2.86 B | USA |
 |
STAAR Surgical Company
STAA
|
$ 19.8 | 1.62 % | $ 981 M | USA |
 |
STERIS plc
STE
|
$ 209.98 | 0.61 % | $ 20.6 B | USA |
 |
Stereotaxis
STXS
|
$ 1.32 | 2.94 % | $ 120 M | USA |
 |
BioLife Solutions
BLFS
|
$ 37.74 | 0.37 % | $ 1.8 B | USA |
 |
Baxter International
BAX
|
$ 23.49 | 0.17 % | $ 12.1 B | USA |
 |
Utah Medical Products
UTMD
|
$ 75.01 | 2.93 % | $ 243 M | USA |
 |
West Pharmaceutical Services
WST
|
$ 375.87 | 1.29 % | $ 27.2 B | USA |
 |
Becton, Dickinson and Company
BDX
|
$ 182.52 | 0.01 % | $ 52.5 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 9.78 | 0.05 % | $ 1.95 B | USA |
 |
The Cooper Companies
COO
|
$ 56.07 | 1.41 % | $ 11.2 B | USA |
 |
ICU Medical
ICUI
|
$ 163.32 | 1.45 % | $ 4.02 B | USA |
 |
Milestone Scientific
MLSS
|
$ 0.42 | 4.73 % | $ 34.5 M | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
Teleflex Incorporated
TFX
|
$ 121.75 | 0.08 % | $ 5.43 B | USA |
 |
ResMed
RMD
|
$ 222.3 | 0.15 % | $ 32.3 B | USA |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
Ekso Bionics Holdings
EKSO
|
- | - | $ 28.6 M | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
Masimo Corporation
MASI
|
- | - | $ 9.59 B | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 31.1 M | USA |